Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Position Lifted by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 11.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 46,897 shares of the company’s stock after acquiring an additional 4,705 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Syndax Pharmaceuticals were worth $1,013,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP raised its holdings in Syndax Pharmaceuticals by 2.7% during the third quarter. Wellington Management Group LLP now owns 7,642,446 shares of the company’s stock worth $110,968,000 after purchasing an additional 198,262 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Syndax Pharmaceuticals by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,617,302 shares of the company’s stock worth $52,523,000 after buying an additional 34,632 shares in the last quarter. Hudson Bay Capital Management LP raised its stake in shares of Syndax Pharmaceuticals by 160.2% in the 3rd quarter. Hudson Bay Capital Management LP now owns 1,236,186 shares of the company’s stock worth $17,949,000 after buying an additional 761,186 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Syndax Pharmaceuticals by 8.1% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,000,000 shares of the company’s stock valued at $14,520,000 after buying an additional 75,000 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in Syndax Pharmaceuticals by 3.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 506,467 shares of the company’s stock valued at $7,354,000 after buying an additional 15,156 shares in the last quarter.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $20.97 on Wednesday. Syndax Pharmaceuticals, Inc. has a 52 week low of $11.22 and a 52 week high of $25.34. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -7.08 and a beta of 1.03. The company has a 50 day moving average price of $22.76 and a 200 day moving average price of $19.48.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, February 27th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same period last year, the business earned ($0.62) earnings per share. Equities analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

SNDX has been the topic of several research reports. Scotiabank cut shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and dropped their price target for the stock from $36.00 to $23.00 in a research report on Wednesday, January 31st. StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a report on Friday, January 19th. JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Finally, HC Wainwright restated a “buy” rating and issued a $41.00 price target on shares of Syndax Pharmaceuticals in a research report on Wednesday, March 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $34.42.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).